Payload Information
General Information of This Payload
| Payload ID | PAY0AJCVM |
|||||
|---|---|---|---|---|---|---|
| Name | B61 |
|||||
| Synonyms |
B61
Click to Show/Hide
|
|||||
| Target | Eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) | |||||
| Structure |
|
|||||
| Formula | C29H34ClN5O5 |
|||||
| Isosmiles | O=C1C(C=CC(CNC(NC(C=C2)=CC(Cl)=C2CCCOC3CCNCC3)=O)=C4)=C4CN1C(CCC5=O)C(N5)=O |
|||||
| InChI |
InChI=1S/C29H34ClN5O5/c30-24-15-21(5-4-19(24)2-1-13-40-22-9-11-31-12-10-22)33-29(39)32-16-18-3-6-23-20(14-18)17-35(28(23)38)25-7-8-26(36)34-27(25)37/h3-6,14-15,22,25,31H,1-2,7-13,16-17H2,(H2,32,33,39)(H,34,36,37)
|
|||||
| InChIKey |
ZGHQJFCFSFHREM-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
568.074 |
Polar area |
128.87 |
||
Complexity |
1246.794577 |
xlogp Value |
3.1239 |
|||
Heavy Count |
40 |
Rot Bonds |
9 |
|||
Hbond acc |
6 |
Hbond Donor |
4 |
|||
The activity data of This Payload
| Standard Type | Value | Units | Cell line | Disease Model | Cell line ID | Reference |
|---|---|---|---|---|---|---|
| Half maximal inhibitory Concentration (lC50) | <10 | nM |
Ramos cells
|
Burkitt lymphoma
|
[1] | |
| Half maximal inhibitory Concentration (lC50) | <10 | nM |
Ramos cells
|
Burkitt lymphoma
|
[1] | |
| Half maximal inhibitory Concentration (lC50) | <10 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[1] | |
| Half maximal inhibitory Concentration (lC50) | <10 | nM |
HL-60 cells
|
Adult acute myeloid leukemia
|
[1] | |
| Half maximal inhibitory Concentration (lC50) | <10 | nM |
SK-BR-3 cells
|
Breast adenocarcinoma
|
[1] | |
| Half maximal inhibitory Concentration (lC50) | <10 | nM |
SK-BR-3 cells
|
Breast adenocarcinoma
|
[1] | |
| Half maximal inhibitory Concentration (lC50) | <10 | nM |
NCI-H929 cells
|
Plasma cell myeloma
|
[1] | |
| Half maximal inhibitory Concentration (lC50) | <10 | nM |
NCI-H929 cells
|
Plasma cell myeloma
|
[1] | |
| Half maximal inhibitory Concentration (lC50) | 10-50 | nM |
NCI-H82 cells
|
Lung small cell carcinoma
|
[1] | |
| Half maximal inhibitory Concentration (lC50) | 10-50 | nM |
NCI-H82 cells
|
Lung small cell carcinoma
|
[1] |
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
wO2024222841A1 ADC44 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
79.60%
|
High HER2 expression (HER2+++) | ||
| Method Description |
Investigated the antitumour effect of 3mg/kg ADC in a HER2high HCC-1954 xenograft NUNU mice tumour model, D21.
|
||||
| In Vivo Model | HER2-high HCC-1954 xenograft NUNU mice tumour model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | < 15 pM | High HER2 expression (HER2+++) | ||
| Method Description |
Cytotoxicity of ADC to SK-BR-3 cells
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
wO2024222841A1 ADC44-4 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
15-25 pM
|
High HER2 expression (HER2+++) | ||
| Method Description |
Cytotoxicity of ADC to SK-BR-3 cells
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||